Johnson & Johnson $JNJ Stock Holdings Lowered by AEGON ASSET MANAGEMENT UK Plc

Key Points

• AEGON ASSET MANAGEMENT UK Plc cut its Johnson & Johnson stake by 10.4% in the first quarter, selling 60,861 shares and leaving it with 524,731 shares worth about $128.2 million.
• Analysts remain generally positive on JNJ, with a “Moderate Buy” consensus and an average price target of $253.04. Several firms recently raised their targets, including HSBC, JPMorgan, and Morgan Stanley.
• Johnson & Johnson recently reported solid quarterly results, beating EPS and revenue estimates, and also raised its dividend to $1.34 per share. The company is additionally investing more than $1 billion to expand its Jacksonville Vision operations as part of a broader U.S. manufacturing push.

AEGON ASSET MANAGEMENT UK Plc trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.4% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 524,731 shares of the company's stock after selling 60,861 shares during the period. Johnson & Johnson comprises approximately 1.7% of AEGON ASSET MANAGEMENT UK Plc's investment portfolio, making the stock its 12th biggest position. AEGON ASSET MANAGEMENT UK Plc's holdings in Johnson & Johnson were worth $128,151,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares during the last quarter. United Bank lifted its holdings in shares of Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company's stock valued at $1,539,000 after purchasing an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC boosted its position in shares of Johnson & Johnson by 13.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company's stock valued at $896,000 after purchasing an additional 692 shares during the period. Wealth Group Ltd. boosted its position in shares of Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company's stock valued at $226,000 after purchasing an additional 168 shares during the period. Finally, Schnieders Capital Management LLC. increased its stake in Johnson & Johnson by 9.8% in the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company's stock worth $11,255,000 after purchasing an additional 6,584 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on the company. Bank of America boosted their price objective on Johnson & Johnson from $253.00 to $254.00 and gave the stock a "neutral" rating in a report on Wednesday, April 15th. HSBC boosted their price target on shares of Johnson & Johnson from $265.00 to $280.00 and gave the company a "buy" rating in a report on Tuesday, March 17th. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $250.00 to $260.00 and gave the company a "neutral" rating in a research report on Wednesday, April 15th. Morgan Stanley set a $283.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, April 15th. Finally, Stifel Nicolaus boosted their target price on shares of Johnson & Johnson from $220.00 to $250.00 and gave the company a "hold" rating in a research note on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average price target of $253.04.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson announced a more than $1 billion expansion of its Jacksonville, Florida Vision operations, boosting domestic manufacturing, packaging, and distribution capacity for ACUVUE contact lenses. The move is part of a broader $55 billion U.S. investment plan and may support long-term growth and supply-chain resilience. Johnson & Johnson (JNJ) Is Spending More Than $1 Billion On Jacksonville Vision Expansion
• Positive Sentiment: Recent commentary highlights Johnson & Johnson as a quality dividend name with improving pharma momentum, including oncology strength and upside to price targets, which may be helping sentiment around the stock. Pharma Momentum Fuels Johnson & Johnson’s Path to Double-Digit Upside
• Neutral Sentiment: Brokerage coverage remains constructive, with Johnson & Johnson still carrying a “Moderate Buy” consensus rating. This supports the stock, but is not a fresh catalyst on its own. Johnson & Johnson NYSE: JNJ Receives Consensus Rating of "Moderate Buy" from Brokerages
• Neutral Sentiment: Additional articles reiterated the Jacksonville expansion story and its strategic role in strengthening JNJ’s Vision business, reinforcing the same positive theme rather than adding a new development. How Johnson & Johnson (JNJ) Is Using U.S. Manufacturing Investment to Strengthen Its Vision Business
• Negative Sentiment: No major negative company-specific headlines were included in the latest batch, so there is little evidence of a fresh catalyst pushing shares lower today.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the business's stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

JNJ stock opened at $231.12 on Tuesday. The stock has a market cap of $556.36 billion, a P/E ratio of 26.72, a P/E/G ratio of 2.24 and a beta of 0.26. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The firm has a 50 day simple moving average of $230.41 and a 200 day simple moving average of $228.43. Johnson & Johnson has a 52 week low of $149.74 and a 52 week high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. During the same quarter last year, the business posted $2.77 EPS. The company's revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Research analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were given a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, May 26th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. Johnson & Johnson's payout ratio is 61.97%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.